Late outcomes of congenital and childhood non-immune, isolated atrioventricular block: a French nationwide retrospective cohort study
Authors' conclusion
In this large nationwide study, the long-term outcome of congenital or childhood non-immune, isolated AVB was excellent.
Study context
- Population
- Children with congenital or childhood non-immune, isolated atrioventricular block (AVB) diagnosed in utero up to 18 years, 29 French centres, 1980–2022; structural heart disease, endomyocardial fibrosis or maternal antibodies excluded
- Participants
- 385 children · 29 French centres
- Outcome
- Long-term outcomes
- Follow-up
- Median 10 years (5-17)
Methodological detailsnationwide, multicentre
- Nationwide
- Multicentre
Main finding
As reported in the abstract
- Death, endomyocardial fibrosis or dilated cardiomyopathy
- 0
- Permanent pacemaker
- 286/385 (74.3%)
- Pacemaker implanted in first year of life
- 39 (14%)
- Pacemaker implanted before 10 years of age
- 172 (60%)
- Prophylactic pacing indication
- 203 (71%)
Observational data: associations, not effects.
Further findings
Progression to complete AVB in incomplete AVB · 12 years (7-17)
- Progression to complete AVB
- 84/122 (68.8%)
AVB at diagnosis
- Asymptomatic
- 314 (81.6%)
- Complete AVB
- 263 (68.3%)
Genetic screening
- Genetic screening performed
- 133/385 (34.5%)
- Clinically actionable variant identified
- 11 (8.3%)
Original publication
Late outcomes of congenital and childhood non-immune, isolated atrioventricular block: a French nationwide retrospective cohort study. Europace. Published 11 March 2025. doi:10.
Summarised from the published abstract; every number is checked against it